Clinical Evidence and Safety Profile of Combination Use Multiple randomized controlled trials support the safety and efficacy of DPP-4/GLP-1 combination therapy
Bjrklund G, Crisponi G, Nurchi VM, Cappai R, Buha Djordjevic A, Aaseth J
Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, Jahoor F
BioWorld - Saturday, July 25, 2026 See today's BioWorld Home GLP-1s and more weigh in at ADA To read the full story, subscribe or sign in
The anti-obesity segment is growing faster than any other major pharmaceutical category
Preclinical studies suggest that GLP-1 receptor activation in the mesolimbic dopamine system appears to modulate dopamine signaling, which is central to the rewarding effects of alcohol and other addictive substances